Anticoagulants can enhance the efficacy of antiangiogenic therapies by reducing thrombosis, which is promoted by tumor-induced procoagulant activity. Careful dosing is crucial to prevent bleeding while inhibiting tumor growth.

Combining anticoagulants with antiangiogenic drugs may intensify bleeding risks, requiring strict monitoring of coagulation parameters to balance effective cancer treatment with clot prevention.

Anticoagulants and antiangiogenic therapies may synergistically reduce vascular abnormalities and tumor growth, but the dual approach demands meticulous management to avoid adverse effects like excessive bleeding.